trending Market Intelligence /marketintelligence/en/news-insights/trending/mqomoaowisvoeec1eozbvw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

NICE rejects Bayer's liver cancer drug

Benefits of Leveraging a Comprehensive Project Finance Credit Assessment Scorecard

Traditional Multichannel Video Plummets In Rural Areas

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

Case Study: A Utility Company Efficiently Sharpens Its Focus on the Credit Risk of New Customers


NICE rejects Bayer's liver cancer drug

The U.K.'s National Institute for Health and Care Excellence rejected another oncology drug, this time Bayer AG's Sorafenib for use in patients with liver cancer.

The government body, which evaluates drugs for use in the National Health Service, said the drug did not provide enough benefit to justify its high cost.

NICE, however, said that Sorafenib should continue to be recommended for use within the Cancer Drugs Fund.

NICE's recommendation against the use of the drug under the NHS is preliminary and the government body is open to consultation. NICE also recently rejected Roche Holding Ltd.'s breast cancer drug Kadcyla on financial grounds.